ALLO
Allogene Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.97
−0.51%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.6M | — | 22.0K | 95.0K | 156.0K |
| Cost of Revenue | 37.1M | 12.4M | — | — | 14.3M |
| Gross Profit | (32.5M) | (12.4M) | 22.0K | 95.0K | (14.1M) |
| Operating Expenses | |||||
| R&D Expense | 119.7M | 150.2M | 192.3M | 242.9M | 256.4M |
| SG&A Expense | 62.4M | 56.8M | 65.2M | 71.7M | 79.3M |
| General & Admin Expense | 62.4M | 56.8M | 65.2M | 71.7M | 79.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (34.2M) | (12.4M) | 15.7M | 13.2M | (14.3M) |
| Total Operating Expenses | 147.9M | 194.6M | 273.2M | 327.8M | 321.4M |
| Cost and Expenses | 185.0M | 206.9M | 273.2M | 327.8M | 335.7M |
| Operating Income (EBIT) | (180.3M) | (206.9M) | (273.2M) | (327.7M) | (335.5M) |
| Non-Operating | |||||
| Interest Income | 15.8M | 19.3M | 20.2M | 18.3M | 4.6M |
| Interest Expense | 1.3M | 1.1M | 181.0K | — | — |
| Net Interest Income | 14.5M | 18.2M | 20.0M | 18.3M | 4.6M |
| Other Non-Op Income/Expense | 14.8M | 16.0M | 16.1M | 472.0K | (4.9M) |
| Non-Operating Income (excl Interest) | (16.1M) | (17.1M) | (16.2M) | (472.0K) | 4.9M |
| EBT (Pre-Tax Income) | (165.5M) | (190.9M) | (257.1M) | (327.3M) | (340.4M) |
| Income Tax Expense | — | — | 443.0K | — | — |
| Bottom Line | |||||
| Net Income | (165.5M) | (190.9M) | (257.6M) | (327.3M) | (340.4M) |
| Earnings from Cont. Ops | (165.5M) | (190.9M) | (257.6M) | (327.3M) | (340.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (165.5M) | (190.9M) | (257.6M) | (327.3M) | (340.4M) |
| Per Share | |||||
| Basic EPS | ($0.67) | ($0.87) | ($1.32) | ($2.09) | ($2.38) |
| Diluted EPS | ($0.67) | ($0.87) | ($1.32) | ($2.09) | ($2.38) |
| Revenue Per Share | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 328.9M | 220.6M | 194.8M | 156.9M | 143.1M |
| Diluted Shares Outstanding | 328.9M | 220.6M | 194.8M | 156.9M | 143.1M |
| Profitability Metrics | |||||
| EBITDA | (152.5M) | (177.5M) | (243.3M) | (313.1M) | (326.1M) |
| D&A | 11.7M | 12.4M | 13.6M | 14.2M | 14.3M |
| EBIT | (164.2M) | (189.8M) | (257.0M) | (327.3M) | (340.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026